Dr. Amit Kumar works as a Associate Director in Medical and Hemato Oncology at Jay Prabha Medanta Super Speciality Hospital in Patna. He received his MBBS from PMCH in Patna and his MD (General Medicine) from the Institute of Medic al Scienc es ,BHU in Varanasi. He obtained DNB (Medical Onc ology) and DM (Medic al Oncology) degrees from Tata Memorial Hospital in Mumbai. He also earned an MRCP SCE (Medical Oncology) and is an European Certified Medical Oncologist. He is an expert in chemotherapy, immunotherapy,targeted therapy and bone marrow / stem cell transplantation. He practices both solid malignancies (Head and Neck, Lung, Breast, GI, GU, Gynaecological cancers and bone and soft tissue sarcomas) and haematolymphoid malignancies ( leukemia, lymphoma and myeloma). His special interest is in Geriatric Oncology and Rare tumours diagnosis and management. He has also been awarded the Gold Medal in MD (General Medicine)

Clinical Trials

1. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.
2. Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study
3. Phase 3 randomized study comparing docetaxel-platinum with docetaxel-platinum-5 fluorouracil as neoadjuvant chemotherapy in technically unresectable oral cancer.

Selected publications

1. Kumar A, Noronha N, Patil VM, Joshi A, Menon N, Kapoor A, Kumar R, Mahajan A, Janu A, Shetty O,  Prabhash K.   Efficacy and safety of Lorlatinib in subsequent lines of therapy in ALK and ROS 1 positive lung cancer. ESMO ASIA 2020 Nov. Annals of Oncology (2020) 31 (suppl_6): S1386-S1406. 10.1016/annonc/annonc367
2. Kumar A, Noronha N, Patil VM, Joshi A, Menon N, Kapoor A,Prabhash K. Efficacy and safety of low dose immunotherapy in palliative settings of advanced solid tumours. ESMO 2020 Sep. DOI: 10.1016/annonc/annonc279
3. Amit Kumar, Vanita Noronha, Vijay Maruti Patil, Amit Joshi, Nandini Sharrel Menon, and Kumar Prabhash. Long-term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy. Journal of Clinical Oncology 2020 38:15_suppl, e18507-e18507 
4.  Kumar A, Pramanik R, Raj S, Ahmed A, Kumar L. Acute Kidney Injury in Newly Diagnosed Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy: Experience of a Tertiary Cancer in India. Annals of Oncology (2017) 28 (suppl_10): x94-x99. 10.1093/annonc/mdx664(Impact factor-14.196)
5. Ramaswamy A, Nayak L, Roy Moulik N, Sengar M, Chinnaswamy G, Jobanputra K, Shah MJ, Kapoor A, Joshi A, Kumar A, Gokarn A, Bonda A, Cheriyalinkal Parambil B, Prasad M, Bagal B, Dhamne C, Narula G, Jain H, Ghosh J, Thorat J, Bajpai J, Menon N, Khattry N, Bhargava P, Punatar S, Gulia S, Banavali S, Gupta S, Srinivas S, Rath S, Vora T, Noronha V, Patil VM, Ostwal V, Prabhash K. COVID-19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Med. 2020 Dec;9(23):8747-8753. doi: 10.1002/cam4.3423. Epub 2020 Oct 31. PMID: 33128509; PMCID: PMC7724305.

Publication in Pipeline

1. Low dose Nivolumab in advanced solid malignancies
2. Outcomes and safety of durvalumab in locally advanced Lung cancer post CTRT in Indian settings
3. Response outcomes of Lorlatinib in subsequent lines in Alk positive NSCLC.